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ABSTRACT 
 
Background 
Depressive disorders place a great burden on society and rank as the fourth leading cause of 
burden among all diseases. (WHO 2001) Antidepressants are the first-line treatment for major 
depressive disorder in Norway. Escitalopram (Cipralex®) is a patented antidepressant and 
therefore more costly than the generic drug citalopram. Since its introduction in the 
Norwegian market in 2002, the market share of escitalopram has increased sharply and 
accounted for NOK 131 mil in 2005. The same year, sales of citalopram were NOK 43 mil. 
By comparing costs and effects of the two drugs, an incremental cost-effectiveness ratio will 
indicate whether switching to escitalopram is a cost-effective option. 
Methods 
The study was based on a decision analytic model (decision tree) developed in Tree Age Pro 
Healthcare Module program for the adult Norwegian patients with major depressive disorder. 
Data used in the model consisted of costs and effectiveness data for citalopram and 
escitalopram. Cost data included relevant costs for each of the treatments from two 
perspectives: the health care payer perspective and the societal one. Effectiveness data were 
based on clinical trials. The time perspective of the model was six months. Health 
consequences were measured in terms of symptom reduction and translated into the quality- 
adjusted life years (QALYs). In one-way sensitivity analyses on all parameters, the results 
were, in the societal perspective, robust for all parameters except for the  probability of a good 
response in the escitalopram group. When lower bound (0.39) was used for good response 
rate in escitalopram group, results have changed so that escitalopram was not cost-effective.  
Results
The proportion of patients who had symptom reduction after six months increased by 5% 
(from 80% to 85%) by replacing citalopram with escitalopram. When indirect costs were 
taken into consideration (societal perspective), the cost per additional successfully treated 
patient was NOK 18 600. From the health care payer perspective, this cost was NOK 27 000. 
Assuming that one successful treatment is equivalent to 0.11 QALYs, the cost per QALY was 
NOK 169 000 and 245 000, respectively for the societal and health care perspective. 
Conclusion 
Escitalopram is a cost-effective option for treatment of major depressive disorder in Norway. 
This conclusion is valid for both the societal and the health care payer perspective. 
CONTENT 
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1. Introduction 
 
Increased trends in prescribing antidepressants from the 1990s until the present has increased 
health expenditures in Norway. (Figure 1) Introduction of the new class of antidepressants 
SSRIs that took place in 1990s has had an impact on this increase in expenditures. In 2005, 
sales of antidepressants in Norway were NOK 545 mil. (FHI 2006) Along direct costs related 
to depression, indirect (productivity) costs have increased too. Employed people who suffer 
from depression lose on average 11 working days during a 6-month period, twice that of 
employees who are not depressed. (Lepine, Gastpar et al. 1997) In 2006, the British Journal of 
Psychiatry published a study that estimated depression-related yearly costs for Norway on 
NOK 1,5 billions (Dalgard, McCracken et al. 2006)  
 
High levels of public spending in Norway for depression emphasize the need for cost-
effectiveness analysis of interventions for depression. The pharmacoeconomics of 
antidepressants are complex and there is lack of consistent methodology in this area. Another 
limitation is that different health care systems have different ways of financing health care. 
Economic evaluations until now have mainly compared psychological treatment versus 
antidepressants. There is still limited evidence of cost-effectiveness of antidepressants, to 
some extent due to lack of clinical evidence in head–to-head comparison of different drugs. 
(Barrett, Byford et al. 2005) Results of this analysis may contribute to better allocation of 
health care resources and more efficient and effective use of antidepressants in Norway.  
 
 
 
 
 
 
 
 
 
Figure 1 Sales of three major groups of antidepressants in Norway 1990-2004 in DDD/1000inh (The Norwegian 
Institute of Public Health) 1
                                                   
1 The approved antidepressants and their brand names in Norway (Citalopram=Cipramil®,Citalopram®. Sertralin= Sertralin® Zoloft®. 
Escitalopram=Cipralex®. Paroxetin= Paroxetin®, Seroxat® Fluoxetin= Fluoxetin®, Fontex®). 
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This master thesis consists of an introduction (chapter one), description of methods (chapter 
two), results (chapter three) and discussion (chapter four). The definition, classification, 
diagnostics and epidemiology of depression are explained in chapter one. In addition, 
available treatments are described as well as the most used outcome measurements for 
depression. Furthermore, overview of the studies on cost-effectiveness of the antidepressants 
is given, for Norway as well as for the other countries. Comparators in the analysis and a 
decision tree are described, along the searching strategy used to select studies for model 
inputs. Results for each of the perspectives are presented, health care payer and a societal one, 
as well as sensitivity analysis results. Cost-utility analysis was performed in order to express 
result in terms of cost per QALY gained2. The discussion part summarizes main findings of 
my study, describe the strengths and the limitations and policy implications.  
 
1.1. Definition, classification and diagnostics of depression 
 
Major Depressive Disorder (MDD) is a chronic, recurrent illness associated with morbidity 
and mortality. It is the most common mental disorder and a major cause of disability in the 
world. It is the fourth leading cause of burden among all diseases and will have a growing 
trend during the next 20 years. (WHO 2001) By 2020, it may become the second most 
common cause of disability in the world. (Murray and Lopez 1996) 
 
Mood disorders are classified into bipolar (manic, depressed, mixed) and unipolar mood 
disorder such as major depressive disorder (MDD). If MDD is the main diagnosis, further 
sub-classification depends on whether it is the first episode or a recurrence. When episodes of 
depression recur (between two episodes has to be at least six months) this is called recurrent 
depressive episode. A patient who has had two or more depressive episodes recently and has 
functional impairment related to MDD is considered to suffer from the recurrent depressive 
episode. (NICE 2004) It is difficult to draw a line between normal emotions (i.e. sadness, 
mood swings associated with person’s unwanted life events, cultural/ social setting and 
personality) and a pathological condition. This makes classification and diagnosis in 
psychiatry very difficult. Diagnosis to a large extend depends on the physician’s judgement of 
the patient as well as the patient’s ability to make a distinction between depression symptoms 
and reaction to stressful life events.  
                                                   
2 Quality-adjusted life year 
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According to the severity, depression can be mild, moderate and severe. Other important 
dimensions of depression are chronicity, recurrence and treatment resistance. The bases for 
the classification of the depression severity are scores from depression rating scales. The most 
used instruments administered by physician are the MADRS (Montgomery-Åsberg 
Depression Rating Scale) and the HDRS (Hamilton Depression Rating Scale). BDI (Beck 
Depression Inventory) that is the most used instrument in psychotherapeutic studies is a self- 
assessment instrument. (Åsberg, Bengtsson et al. 2004)  
 
The diagnosis of depression assumes that a person’s professional and personal life is, to a 
certain extent, affected by disease (depending on a severity level). Classification systems 
given in DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) by The American 
Psychiatric Association require five out of nine symptoms for at least two weeks to diagnose a 
major depression.(APA 1994) WHO’s ICD-10 (International Classification of Diseases and 
Impairments) categorize depression as mild, moderate and severe.  
 
Mild depression does not disrupt usual activities. For diagnosis of mild depression, ICD-10 
require the presence at least two out of three general symptoms that last for at least two weeks 
(certain deviation in mood, interest and energy level) and that cannot be explained by other 
physical or mental disturbance. (WHO 1992) In addition, one of seven additional symptoms 
has to be present as well: loss of self-confidence/self-esteem, feeling of inappropriate 
guilt/abnormal self-reproach, death/suicidal thoughts and/or self-destructive behaviour, lack 
of concentration and/or indecisiveness, slowing/agitation in usual activities, sleep disturbance 
and change in dietary habits that results in weight loss/gain.  
 
Moderate depression includes mild depression criteria, along with six additional symptoms 
(out of the seven additional and three general symptoms) for at least a two-week period. A 
moderate depression episode often affects patient’s ability to perform usual activities. A 
patient who has all three general symptoms and at least five out of seven additional ones has a 
diagnosis of severe depression, a disease that is dysfunctional in every way. (Goldman 2000) 
A patient that meets the diagnostic criteria for depression that lasts at least two years is having 
chronic depression. This depression can be mild, moderate or severe. (NICE 2004) 
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1.2. Epidemiology of depression  
 
Reliable epidemiological studies allow better understanding of the depressive disorders. 
During their lifetime, around 10 percent of men and 24 percent of women in Norway will 
develop a severe depression; six to 13 percent of these will still have depression after two 
years. (Kringlen, Torgersen et al. 2001) Mild and moderate depression has been more 
common in the last 50 years while the incidence rate of the severe depression seems to be at a 
constant rate. (Åsberg, Bengtsson et al. 2004)  
 
Are people more mentally ill or can the increase in the incidence rate of mild/moderate 
depression can be explained in a different way? An explanation for this increase can be 
assigned to various factors such as more resources used for research in medicine, easier access 
to health care services, more open communication between physicians and patients and 
influence of mass media on the people’s perception of mental health (de-stigmatization). 
Furthermore, the pharmaceutical industry has financial and human resources that allow it to 
develop and market the new and effective drugs for depression. Prevalence of depression 
varies considerably across countries and among rural and urban areas. This is to some extent 
because studies in different countries have used different measures and sample selection 
procedures.  
 
The European Commission established ODIN (Outcome of Depression International 
Network) in 1996 aiming to provide comparable data on prevalence and risk factors of 
depressive disorders in European rural and urban settings. The aim was further to assess the 
impact of two psychological interventions on the outcome of depression. Norway was one of 
the five countries in the ODIN study (the others being the UK, Ireland, Finland and Spain). 
This study was a cross-sectional two-phase community study. Instruments used were the BDI 
(Beck Depression Inventory) in Phase I and SCAN (Schedule for Clinical Assessment in 
Neuropsychiatry) in Phase II. The Norwegian rural setting was Rakkestad and the urban 
setting was Oslo. Studies have found a higher proportion of depression among the female 
population in urban areas. The prevalence was higher among women, as observed in previous 
studies. (Bebbington, Sturt et al. 1984; Weissman, Bland et al. 1996) Social, medical and 
genetic factors may explain this inter-gender difference in prevalence of depression.  
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The initial sample for Norway included 2444 individuals from the urban area and 2464 from 
the rural. The first phase completed 1456 individuals from the urban and 1594 individuals 
from the rural area. Out of these 53.9% were female in the urban area and 51.8 % female in 
rural area. Based on the results of this study, prevalence of depressive episode in Norway is 
7% in the urban area (mean), CI 95% (4.6-10.4); and in the rural area mean is 8.4% (4.0-16. 
8). Weighted prevalence of MDD (DSM-IV criteria) in urban area was 7% (4.7-10.2). Out of 
these 9.4% were females and 4.6% males. Rural area had prevalence of 8.48% (4.17-16.7). 
Out of these, 10% was prevalence for females and 5.81% for males. For comparison, the 
global sample of the five European countries had a total prevalence of 6.6% (5.4-8.4). Out of 
these 7.9% was the prevalence for females and 5.2% for males. (Ayuso- Mateos, Vazquez-
Barquero et al. 2001)   
 
The Lundby epidemiological study took place in 1947 in the Lundby area in the south of 
Sweden. It was designed as a prospective, longitudinal study on a total population of 3563 
subjects over a 50 year time- period (1947-2007). Follow-up studies were carried out in 1957 
and in 1972. In 1997 the surviving subjects (N=1797) were interviewed by psychiatrists with 
a semi-structured interview. The results showed that in both periods women had higher 
incidence rates than men. The average annual incidence rate was lower for women and tended 
to be lower for men in 1972-1997 as compared with 1947-1972. The cumulative probability 
for developing depression was 22.5% for men and 30.7% for women from 1972-1997. In the 
period 1947-1972, these figures were 22.8% for men and 35.7% for women. Lower annual 
incidence rates were observed from 1972-1997 than in period from 1947-1972. These 
findings suggest that the trend of increasing rates of depression in the Lundby cohort has 
ended. Incidence rates for depression were higher for women than for men, indicating 
importance of inter-gender differences.  (Mattisson, Bogren et al. 2005)  
 
Another two-phase epidemiological population study was carried out in Norway between 
1989 and 1991 to assess occurrences of psychiatric diseases. A random sample included 
people from the Lofoten islands (rural area) and from Oslo (urban area). The first screening 
phase has completed 1879 persons who administered self- administered Hopkins Symptom 
Check List 25 items (HSCL- 25) and participated in an in-person interview. An HSCL-25 
score greater than or equal to 1.55 indicated a “possible psychiatric case”. Out of 534 persons 
who met this criterion, 119 refused to participate in a second phase, thus 415 entered the 
second phase. A random sample of persons with the lower HSCL-25 scores was selected to 
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Phase II. Out of 263 persons, 61 refused to participate leaving 202 persons. Finally, 617 
persons were interviewed with the Composite International Diagnostic Interview (CIDI). In 
this study a symptom score in HSCL-25 of 1.75 or more was found in 19.8% of females and 
9.3% of males; ratio 2.1:1 (HSCL-25 score greater or equal to 1.75 indicates a psychiatric 
case). In addition, the number of cases was significantly higher in the oldest age group 
compared to the youngest.  
 
There were no significant differences between rural and urban areas, but inter-gender and 
inter-age differences were present. Incidence rate for depression (ICD-10) was 2.6% in all 
ages (20-79), with CI 95% of (1.3-4.0). Out of these, females accounted for 4.3 % with CI 
95% (1.8-6.8) and males 0.7% with CI 95% (0.1-1.4). The incidence rate of the first episode 
of psychiatric disorders was 2.7 (per 1000 persons per year). Incidence rate of depression, 
anxiety and somatoform disorders has increased significantly from 3.3 in 1930 to 12.8 in 
1991. (Sandanger, Nygard et al. 1999) 
 
 Although the first depressive episode in most patients will spontaneously end after six 
months, depression has a strong tendency for recurrence and becoming chronic. Each new 
depressive episode increases the probability of a recurrent episode (after the first episode 
about 50% patients will have a second one, and about 70% of these will have a third episode). 
Intervals between episode occurrences are shorter every time. The problem is lack of long-
term follow-up studies on primary care patients. Studies until now have shown significant 
gender (more women), age (aging and co-morbidity can partly explains this), ethnic (i.e. 
black/ Hispanic in USA or immigrants in Norway are more depressed) and geographical 
differences in incidence rates for depression.  
 
Social differences have been observed too as depression can be related to poverty, constrained 
access to health care and illiterate people not able to understand and report illness. It seems 
clear that there is relationship between depression and other mental illnesses and/or other 
somatic chronic diseases (diabetes, MS, cancer, substance abuse, psychosis, schizofrenia). 
However, it is not clear whether or not the relationship is causal or structural (substance abuse 
as a cause of depression, depression as a cause of substance abuse, or none of these). Along 
with gender and income inequalities, culture is one important factor that differs between 
societies and has an impact on the epidemiology of depression. (Patel 2001) 
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1.3. Treatments for depression 
 
Depending on severity (mild/moderate/severe) and type of depressive disorder 
(unipolar/bipolar), age of the patient (child/adolescent/adult/elderly) and medical history 
(presence of the psychiatric disorder in family) treatments for depression include 
antidepressants, psychotherapy, electroconvulsive therapy (ECT), phototherapy, alternative 
medicine or combination of these.  
 
First-line treatment for depression is pharmacotherapy. The first effective antidepressant drug 
was discovered in the 50’s. Iproniazid, a monoamine oxidase inhibitor (MAOi) was originally 
an antitubercular drug. Imipramine, tricyclic antidepressant (TCA), was developed in 1957. 
Both drug classes, MAOi and TCAs are interacting with the monoamine systems: amines: DA 
(dopamine), noradrenalin (NA or norepinephrine) and 5-hydroxytryptamine (5HT or 
serotonin). TCAs increase serotonergic function by blocking serotonin reuptake. Interesting is 
that drug was actually invented before the mechanism of the disease was discovered. During 
the 60’s and based on the action of the drugs, scientists proposed an hypothesis in order to 
explain the cause of depression. Ashcroft believed that the lack of serotonin was the cause of 
depression. (Ashcroft, Crawford et al. 1966) In 1965, Schildkraut stated that noradrenalin 
might play a key role in the aetiology of depression. (Schildkraut 1965)  
 
An abnormal function in the serotonin transmitter system can cause depression. The focus in 
treatment of depression has moved from turnover of neurotransmitters to receptor regulations 
and lately to intracellular changes. New generation antidepressants were designed as selective 
serotonin reuptake inhibitors (SSRIs). In 1993, Seroxat® (paroxetin) was the first SSRI 
introduced into the Norwegian market. Even though it is known that they have an effect on 
major neurotransmitters in the central nervous system (CNS), the mechanism of action of the 
second-generation antidepressants is poorly understood.  Three main therapeutic classes of 
atidepressants consists of TCAs or old generation antidepressants while the SSRIs make the 
new generation of antidepressants. There is also a class known as other newer 
antidepressants, or serotonin-norepinephrine reuptake inhibitors (SNRIs). SSRIs are better 
tolerated than antidepressants of the old generation (TCAs), have fewer adverse effects and 
therefore fewer withdrawal symptoms. When compared to new generation antidepressants, 
TCAs do not differ in efficacy but in a poorer tolerability profile.  
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In 1968, Carlsson discovered that antidepressants can block the reuptake of serotonin and this 
discovery led to a development of a compound that selectively blocked the reuptake of 
serotonin, without acting on noradrenaline. 
Such agents are known as SSRIs. In order to understand the mechanism of SSRIs, it is 
necessary to clarify terms such as synapse; link through which brain cells “communicate”.   
 
 
Figure 2 Transmission of information in the brain is taking place through synapse3
    
          Figure 3 Nerve activity (not depressed)   Figure 4 Reduced nerve activity (depression  
 
Figure 5 SSRI blocks reuptake of transmitters and increased messages passes.4
Figure 5, in a simplified way, illustrates a mechanism of SSRIs action. The hypothesis is that 
in some patients too little serotonin (or noradreneline) is the cause of a depressed mood. 
When a new impulse comes, there are more transmitters and a stronger message is passed. 
                                                   
3 Figures are from Norfolk&Waveney. (2007). "NWMHP Pharmacy Medicine Information."   Retrieved 7.5.2007, from http://www.nmhct.nhs.uk/Pharmacy/.  
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Consequently, activity in that part of the brain is increased. SSRIs are supposed to correct the 
effect of the lack of transmitters.  
 
Figure 6  illustrates a synaptic gap between two serotonergic neurones. The nerve impulse 
“travels” to the postsynaptic neurone across the synaptic cleave due to the release of serotonin 
from the presynaptic neurone into the synaptic cleft. Molecules of serotonin are removed from 
the synaptic gap into the presynaptic neurone by the 5-HT transporters’. This reuptake process 
can be inhibited by compounds such as 5-HT reuptake inhibitors (SSRIs). (Sanchez 2006)  
 
In 2000, Carlsson (University of Gothenburg, Sweden), Greengard (Rockefeller University, 
US) and Kandel (Columbia University, US) won The Nobel Prize in Physiology or Medicine 
for their half a century research in neuroscience. Carlsson’s central discovery, that  led to 
treatments of Parkinson’s disease and schizophrenia, was that dopamine is a key 
neurotransmitter in the brain. Greengard has figured out the way on which dopamine and 
other neurotransmitters activate their target neurons when they attach to the synapse. Based 
on the findings of Carlsson and Greengard,  Kandel has demystified important features of 
learning and memory. Further research on the connections between neurotransmitter levels 
and mental states led to discovery of antidepressants such as Prozac. (Stock 2001)  
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In patients who have serious psychosocial problems and/or did not respond well on drug 
treatment, psychotherapy can be an alternative to the drugs (cognitive, behavioural and 
interpersonal) and as effective as drugs. (Brown, Schulberg et al. 1996) In most of the patients 
for whom drug treatment is not sufficient, psychotherapy in combination with drugs can be 
the optimal treatment. In patients with severe, psychotic and manic episodes and only if other 
treatment options are exhausted (no remission or reduction of symptoms), ECT is required.  
 
Various treatments for depression have been seen differently across cultures. The public 
views on the ECT and to the admission to the hospital negatively and people believe that 
these treatments are more harmful than useful. (Jorm 2000) ECT can be assessed as right 
unilateral (only on the right side of the brain, shown in trials as having fewer cognitive effects 
than bilateral) or as bilateral (both sides). (APA 2000) Bilateral ECT results also in rapid 
initial response and high rates of sustained response and remission. (Husain, Rush et al. 2004)  
 
Other somatic treatments like magnetic seizure therapy and vagal nerve stimulation may be 
beneficial, but evidence is not sufficient to recommend its use in clinical practice. (APA 
2000) Systematic review of psychotherapy and pharmacotherapy has concluded that 
combination of these two treatments is more effective than pharmacotherapy alone. 
(Pampallona, Bollini et al. 2004) The stigma that is associated with mental disorders can be a 
deterrent to seeking professional help. (Jorm 2000) A minority of people who meet depression 
diagnostic criteria will look for professional help. (Narrow, Regier et al. 1993)  
 
Therefore, self-help such as physical activity, engaging in pleasurable activities and support 
from family and friends are of great importance. Due to lack of evidence of effectiveness of 
the self-help interventions, it is difficult to claim which are more effective. (Jorm 2000) Social 
support seems to be effective in mild depression (Bridges, Goldberg et al. 1992) as well as 
physical exercise. (Martinsen 1994)  
 
St John’s wort is proven effective in treating mild depression. Some other RCT have also 
shown St John’s wort more effective than placebo, (Kalb, Trautmann-Sponsel et al. 2001) or 
more effective than antidepressants. (Schrader 2000) Contrary, other trials have not shown St 
John’s wort to be more efficient than placebo (Shelton, Keller et al. 2001) or than other 
antidepressants. (Behnke, Jensen et al. 2002) Shared responsibility for depressed patients with 
regular and open communication between primary care physicians, psychiatrists, patients and 
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their family members is necessary. Further, disease management programs, telephone support 
and patient education can improve the effectiveness of drug treatment. More studies in the 
future should evaluate effectiveness of counselling, psychological treatment for severe 
depression and physical exercise in mild to moderate depression.  
 
1.4. Outcome measurements for major depressive disorder 
 
CEAs that compared interventions for depression used nearly 30 different outcome 
measurements (scales) to express effectiveness. Primary outcomes were depression-free day, 
quality of life, successfully treated patients, hospitalization, social adjustment and relapses 
avoided. Most of the studies have used the health care payer perspective for considering costs; 
few have used the societal one. (Barrett, Byford et al. 2005)  
 
Commonly used outcomes related to MDD are presence of depressive symptoms; social and 
occupational functioning, quality of life, hospitalization, self-harm, relapse of depressive 
symptoms and adverse event rates. (Geddes and Butler 2002) The impact of major depression 
on patients’ functioning and quality of life can be measured with the SF-36 (Short Form 36), 
Quality of Life in Depression Scale and the EQ-5D. (Sapin, Fantino et al. 2004) The “Guide 
to Treatments that Work” names trial outcomes in terms of symptom severity scales such as 
the Beck Depression Inventory (BDI), Hamilton Rating Scale for Depression (HAMD-25) 
and Hamilton Rating Scale for Depression (HRSD). (Gorman 2002)  
 
HRSD/HAMD-25 is observer-based disease-specific rating scale. The BDI is a patient-based 
disease-specific rating scale. The Quality of Life scale is a patient- based non-disease specific 
scale of global functioning. The Patient Heath Questionnaire, 9-item (PHQ-9), a newer 
depression severity scale, is brief and includes one functional status item. The Diagnostic 
Interview Schedule (DIS) and the MADRS are often used in the depression studies.  
 
In this analysis, the main outcome is expressed as a dichotomous variable symptoms reduced 
and symptoms persist. Whether a patient (after six months treatment with citalopram or 
escitalopram) have depression symptoms reduction or not, depends on the difference in the 
MADRS score measured at the baseline and after week 24.5 (Colonna, Andersen et al. 2005) 
MADRS is an depression rating scale that measures overall severity of depressive symptoms 
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by a brief 10-item checklist. A person who has at least 30 in MADRS score is considered to 
have major depressive disorder. This score is one of the conditions for a person to enter a 
clinical trial with antidepressants. The Hamilton Anxiety Scale (HAMA or HAS) is a 14-item 
test that measures the severity of anxiety symptoms in children and adults. It is also used in 
measurement of the efficacy of the medications for anxiety. This instrument measures overall, 
somatic and psychic anxiety.   
 
CGI-S scale is a three-item scale used to assess treatment response in psychiatric patients such 
as severity of Illness, global improvement and the efficacy index. Item one is rated on a 
seven-point scale (one is normal, seven extremely ill); item two on a seven-point scale (one is 
very much improved to seven very much worse) and item three on a four-point scale (from 
none to good therapeutic effect). The Global Improvement item requires the clinician to rate 
how much the patient's illness has improved or worsened relative to a baseline state. 
Compared to the condition at baseline, a patient's state is compared to change over time, and 
rated from the very much improved to the very much worse.  
 
Severity of illness rated on the CGI scale is based on the rater’s subjective views of symptom 
severity, which can make interpretation of scores difficult. (Spearing, Post et al. 1997) For 
this reason, I have not used CGI-S outcome data that was used as a secondary outcome 
measurement in the trial by Colonna. (Colonna, Andersen et al. 2005)  
 
1.5. Earlier research on the cost-effectiveness of antidepressants  
 
To find previous research on CEA of antidepressants, I have performed literature search in 
October 2006. Databases searched for cost-effectiveness studies on antidepressants were6 The 
Cochrane library, PubMed, NHSEE Database (National Health System Economic Evaluation 
Database), HTA Database and CCOHTA (Canadian Coordinating Office for HTA). Search 
filter consisted of terms such as cost, depression, antidepressant, SSRI, SNRI and TCA. These 
terms were combined with terms such as health technology assessment, pharmacoeconomic, 
economic evaluation, cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis, 
and cost of illness. Filter for date of publication was not limited at the beginning.  
 
                                                                                                                                                               
5 If a patient has MADRS score ≤12 at week 24, patient has symptoms reduced. If MADRS score is >12, patient has symptoms persist.    
6 For the search results see Appendix I 
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After I have narrowed my research question to citalopram and escitalopram, further literature 
search was from year 2002 since escitalopram was introduced into the market that year.     
  Most of the relevant analyses found have used costs combined with a single disease-specific 
outcome measure, e.g. score from depression scale. Clinical efficacy of the SSRIs is similar to 
TCAs; except that SSRIs are associated with lower rates of non-compliance and treatment 
discontinuation attributed to adverse effects. (MacGillivray, Arroll et al. 2003) CEA of 
escitalopram vs. venlafaxine in Germany resulted in cost-effectiveness of escitalopram. 
(Kulp, von der Schulenburg et al. 2005)  
 
Pharmacoeconomic analysis of the cost-effectiveness of escitalopram vs. citalopram, 
fluoxetine, venlafaxine XR and sertraline was carried out for Finland, Norway, Sweden, 
Belgium and UK. The year of costing was 2000-2001 and the decision analytic models had a 
6-month time horizon. These studies’ results have shown that escitalopram is the more cost-
effective option from the health care provider perspective. (Croom and Plosker 2003) 
 
These studies have limitations such as lack of head-to-head clinical trials comparing 
escitalopram to the other drugs. Model inputs for effectiveness data used in these studies are 
the main limitation in identification of the more cost-effective strategy. Studies that compared 
venlafaxine (SNRI) vs. SSRIs have favoured SNRI over SSRIs in terms of cost-effectiveness. 
(Doyle, Casciano et al. 2001)  Gorman’s pooled analysis of 1321 patients that participated in 
the three placebo-controlled trials for efficacy comparison suggests that escitalopram may 
have faster effect on symptoms than citalopram. (Croom and Plosker 2003) 
 
However, Svensson criticizes Gorman’s analysis for not being transparent in randomization 
and double-blinding method. The pooled analysis did not present a main outcome but stated 
that the main outcome in the three-pooled trials was the mean change in MADRS score from 
baseline to week eight. The analysis was performed on patients who had received at least one 
dose of double-blind medication and had at least one post-baseline MADRS assessment 
(intention-to-treat ITT). The proportion of randomized patients from the each group that were 
not included into ITT population (because of dropping out before the first post-baseline 
assessment) was not reported.  
 
Where there was no significant difference between citalopram and escitalopram, the authors 
described the results with positive phrases as trend toward significance and trends in favours 
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of escitalopram. Analysis mentions six comparisons where citalopram was not superior to 
placebo but no comparisons where escitalopram was not superior to placebo. (Svensson and 
Mansfield 2004)  
 
Although SSRIs appear to be a dominant option over TCAs in many patient groups, available 
evidence on which conclusions are drawn is not strong enough to identify the cost-effective 
strategy. (Barrett, Byford et al. 2005) The Canadian Coordinating Office for Health 
Technology Assessment (CCOHTA) conducted a systematic review of the cost-effectiveness 
of SSRIs compared to TCAs. The main finding was that no antidepressant is a less costly and 
more effective option. (CCOHTA 1997)  
 
Studies that have examined cost-effectiveness of adding counselling to usual care by a GP 
have not found significant differences in costs or effects at the long-term follow-up. (Miller, 
Chilvers et al. 2003; Simpson, Corney et al. 2003) As these studies were measuring clinical 
efficacy of counselling, they might have limitations in identification of significant differences 
in costs. Economic evaluation of couple therapy compared to antidepressants for MDD 
patients has shown couple therapy as cost- effective option. (Leff, Vearnals et al. 2000)  
 
Another meta-analysis of 20 studies and 1020 patients concluded that there is no significant 
difference between escitalopram and other antidepressants on increasing the likelihood of 
remission measured by the MADRS scale. (APA 2000) More than 30 outcome scales used in 
studies makes it difficult to compare results across different studies and interventions. 
(Barrett, Byford et al. 2005) Many studies considered only a narrow definition of costs; 
considering broader costs in depression intervention is of greater importance. There is 
evidence that remission of depressive symptoms more rapidly affects employment status than 
health care service utilization. The economic consequences of depression are influenced 
mainly by the presence of medical co-morbidity than by symptom severity alone. (Chisholm, 
Diehr et al. 2003)  
 
Comparability across economic evaluations is difficult due to large variations in the range of 
costs. In addition, the absence of the standard treatment or universal form of usual care in 
different countries limits comparison between studies and cause the problem of external 
validity. Results from economic evaluations are dependent on assumptions of the model and 
the effectiveness and cost data chosen for the input. In a systematic review of the CUA in the 
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management of depression, pharmacologic interventions generally had lower costs per QALY 
gained when compared to non-pharmacological interventions. When compared to usual care, 
psychotherapy alone, care management alone and combination of psychotherapy and care 
management had lower costs per quality adjusted life year (QALY) gained.  
Generally there is a lack of cost-utility analyses (CUA) in depression studies (e.g. from 539 
CUA at Harvard Centre for Risk Analysis Cost-effectiveness Registry, only one is of 
depression management). (Pirraglia, B. et al. 2004)  None of the CUA, until now, was 
comparing citalopram and escitalopram. Different outcome scales used for effectiveness, 
absence of standard treatment for MDD and difference in health care systems makes 
generalization of results difficult for the other countries.   
 
1.6. Citalopram and escitalopram 
 
New drugs are often a single enantiomer of the existing drug. As the old drugs reach the end 
of their patent life, manufacturers are interested in the production of the single enantiomer 
equivalents, claiming better effectiveness and patenting a new drug. This is known as a chiral 
switching and is claimed to result in improved efficacy and reduced toxicity. Patent protection 
and a awareness of advantage based on promotion rather than clinical evidence will maintain 
high price for single enantiomer drugs. (Mansfield, Henry et al. 2004) Single-isomer drugs 
make up more than fifty percent of the top selling 100 drugs worldwide.7 (Svensson and 
Mansfield 2004) Molecules of citalopram consist of equal amounts of an S- and an R-
enantiomer (mirror-forms).  
 
Pharmacological studies have shown that SSRI activity of citalopram resides almost entirely 
in the S-enantiomer. (Hyttel, Bogeso et al. 1992) By isolating S-enantiomer from citalopram, 
new drug escitalopram was patented in 2002.  
 
S-enantiomer has the highest selectivity for the human serotonin transporter relative to the 
noradrenalin (NA) or dopamine (DA) transporters. (Owens, Knight et al. 2001) In the process 
of isolation of S-enantiomer from citalopram, the assumption was that S-enantiomer, due to 
its therapeutical activity, would have the same efficacy as citalopram, but at half of the dose. 
The tolerability profile of escitalopram is similar to that of citalopram. (Waugh, Goa et al. 
                                                   
7 Citalopram (Cipramil®) was accounted for 78% of Lundbeck’s total turnover in 1999. Lundbeck. (2007). "Company History 1990- 2000." from 
ttp://www.lundbeck.com/aboutus/history/companyhistory/1990/default.asp. h
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2003) Nausea is the most common adverse event of escitalopram. (Croom and Plosker 2003) 
Some RCTs suggest that escitalopram is superior to a placebo in the short-term treatment of 
depression. (Burke, Gergel et al. 2002)  
 
Citalopram is a generic drug, reimbursed in Norway under the brand names Cipramil 
(Lundbeck), Apertia (CNSpharma), Citalopram (Alpharma), Redoxamin (CNSpharma), 
Citalopram Ratiopharm (Ratiopharm), Citalopram Teva (Teva) and Cipramil (Farmagon).8 It 
is produced as 10, 20 and 40 mg tablets. Escitalopram is a reimbursed drug patented by 
Lundbeck in 2002. Escitalopram under the brand name Cipralex is produced by Lundbeck, 
Farlic and Orifarm. It is produced as a liquid (drops) 10 mg/ml and in tablets of 5, 10 and 20 
mg. Citalopram and escitalopram are drugs used for treatment of depressive disorders.   
 
Pharmaceutical companies that fund clinical trials tend to compare drugs to placebo because 
this study design gives higher chance that the drug will be demonstrated as efficient when 
compared to another drug of the same class that is generic, less costly and in many cases 
similar in effectiveness and efficacy. However, escitalopram was not more effective, safer or 
better tolerated than citalopram. (Masilamani, Ruppelt et al. 2003)  
 
Further studies are needed aiming at the comparison of the therapeutic efficacy of 
escitalopram with other antidepressant drugs in different patients and the assessment of the 
effect of the drug on cognitive functions. Escitalopram can therefore be understood a ‘chiral 
chimera’. (Svensson and Mansfield 2004)  
 
 
 
 
 
 
 
 
 
 
1.7. Objective of the analysis   
                                                   
8 From www.legemiddelverket.no 
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 The objective of this study was to answer the research question what are the incremental 
(additional) costs and health consequences of replacing citalopram 20 mg with escitalopram 
10 mg. The method used was a decision analytic model and the period of the analysis is six 
months.  By comparing costs and effects of citalopram and escitalopram in a decision tree 
model, an incremental cost-effectiveness ratio (ICER) of replacing citalopram by escitalopram 
was calculated. Analysis was performed from the health care payer and a societal perspective. 
Besides a health care payer perspective, a societal perspective is taken because depression has 
strong impact on patient’s ability to work and productivity costs have to be included into 
analysis. Furthermore, this often affects their families’ members.  
 
Table 1    
 
INFORMATION ABOUT ANALYSIS 
Research question 
 
What are the incremental costs and health consequences of 
replacing citalopram 20 mg with escitalopram 10 mg  
Analysis Cost-effectiveness analysis 
Program used Tree Age Pro Healthcare Module 2005 
Analytic model Decision tree 
Patient Depressive disorder (DSM-IV), outpatient, male/female, age 
18-65 
Intervention (baseline) Citalopram 20 mg 
Comparator Escitalopram 10 mg 
Primary outcome measure   Symptoms reduced (MADRS score ≤12 at week 24)  and 
symptoms persist (MADRS score >12 at week 24)  
Time perspective  6 months 
Use of health care resources Expert opinion 
Unit costs (for Norway) Market prices (drugs), fee schedules, empirical costs data 
from the three psychiatric hospitals in Oslo   
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2. Methods 
 
2.1. Decision model description  
 
In this analysis, the decision tree examines the cost and health outcomes associated with two 
treatment options (citalopram and escitalopram) over a six-month period in Norway. 
Parameters for the model are based on the RCTs, systematic reviews, clinical guidelines for 
MDD (Anderson, Nutt et al. 2000; APA 2000; Legemiddelverket 2004; NICE 2004; UMHS 
2005) and expert opinion.9  Based on this information, I have developed decision analytic 
model.  
 
The decision tree presents two treatment options, one main branch (strategy) for citalopram 
and the other for escitalopram (Figure 5). The model was developed in the Tree Age Pro 
Healthcare Module 2005 program. Pathways through which patients may flow are identical 
for both alternatives. However, probabilities for each of the pathways are different for two 
drugs and that, along the difference in the resource use, will have impact on results. Results 
will be expressed as a cost per patient with symptom reduction.  
 
In the decision tree, there are three main node types: circle represents probability node (or 
chance), square represents a decision node and at triangle at the end of each pathway is a 
payoff node (terminal). Terminal node (payoff) is the point with the all costs and effects that 
appear from the root node up to payoff node. After six-month period (time of the analysis), 
patient will end up in symptoms reduced or symptom persists health outcome. Other studies 
have used terms such as “depression free”, “successfully treated patient”, or “remission” and 
“relapse” as the health outcomes.  
 
Considering the course and the nature of depression, I wanted to avoid terms like “depression 
free”, since studies and clinical practice have shown that about 50 percent of depressed 
patients who have an initial depressive episode will have recurrence (second depressive 
episode) and out of these, 70 percent will have a third episode. Therefore, I believe “symptom 
reduced” is the more accurate description of what has been measured with MADRS score. An 
economic evaluation for antidepressants in Norway used “remission” and “relapse” for the 
health outcomes. (Francois, Toumi et al. 2003) I argue that in order for depressive episode to 
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be considered as “relapse”, time from the previous episode has to be at least six months. Since 
that model is for six-month period, this health outcome should not be labelled as “relapse”. 
Patient can have remission in symptoms after six months, but cannot have relapse after six 
months.   
 
The root node of the model starts with patients who are candidates for treatment with 
citalopram and escitalopram. The criterion include diagnosis of MDD (DSM-IV diagnostic 
system, MADRS score ≥22 and <40 when entering the trial, called baseline), adult (age over 
18 but less than 65), not suffering or having history of any other mental disorder, not using 
any other antipsychotic, anxiolytic, anticonvulsant drugs or substance abuse. Furthermore, 
patient cannot have other chronic disease(s) and cannot be pregnant.   
 
First, patients in the model receive one daily-defined dose of citalopram (20 mg) or 
escitalopram (10mg) in primary care. A clinician makes this decision. After receiving 
citalopram or escitalopram for 8 weeks (the time SSRIs need to work), clinician will evaluate 
patients for the first time after receiving the treatment. The evaluation is based on difference 
in MADRS score from the baseline to week 8. The MADRS score is the primary parameter of 
antidepressant efficacy. If the score has improved by at least 50 percent from the baseline, 
patient is in responder group. At this point, some of the patients dropped out from the study. 
Other may have no response to the drug, or they may suffer from very unpleasant and strong 
adverse effects. Some of the patients will have a good response to the drug. For each of these 
possible pathways, probabilities are collected from clinical data and are assigned for each of 
the drug. Based on the evaluation of the patients, the clinician will suggest further treatment 
strategy.    
 
As one could expect, patients who have a good response will continue the same treatment on 
the same dose. Patients who had no response to the drug can switch to another antidepressant 
(as recommended to switch to serotonin-norepinephrine reuptake inhibitors SNRI) or can stay 
on the same drug (citalopram/escitalopram) but on an increased dose (citalopram increased on 
28 mg and escitalopram 14 mg based on titration clinical data). Some of the patients with 
intolerable adverse effects will discontinue treatment and be referred to a specialist 
(secondary care), and some will be switched to SNRI. Patients who do not have relief of the 
symptoms after switching to the SNRI (due to non responding to drug or having serious 
                                                                                                                                                               
9 GP currently working in the hospital, specialization in psychiatry interviewed in April 2007, psychiatric hospital in Oslo 
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adverse effects), are referred to the secondary care (specialist care in Norway). After the GP 
refers a patient to a specialist, about 10 percent of the patients will need inpatient care 
(hospitalization), mostly because of self-harm or suicidal thoughts that occurred. The other 90 
percent will be treated in the outpatient specialist care.    
 
In the clinical practice some of the patients can have a partial response to the drug (efficacy is 
not sufficient). In the model these patients will be classified as no response, since treatment 
strategy after no response or a partial response is the same (switch drug or increase dose). 
Some authors included suicide risk into effectiveness studies of SSRIs. (Demyttenaere, 
Hemels et al. 2005) Although suicide is mentioned often in literature as adverse effect of 
SSRI and it is important public health problem, I assumed that there would be no difference in 
suicide risk between citalopram and escitalopram.10 As we are interested in incremental costs 
and effects between two drugs, a suicide risk is not included into the model.  
 
Table 2 Basic model characteristics 
 
Treatment  aim Reduction in symptoms 
Model time Six months 
Outcomes Symptoms reduced (MADRS score ≤12 at week 24) and symptoms 
persist (MADRS score ≥12 at week 24) 
Drop out Discontinued treatment due to intolerable adverse effects 
Increased dose 14 mg for escitalopram (40% increase from DDD) and 28,4 mg for 
citalopram (42,3% increase from DDD) (Lepola, Loft et al. 2003)11
Switch to SNRI If SSRI is not well tolerated, patient is switched to SNRI (venlafaxine) 
 Before prescribing venlafaxine, ECG is recommended (cardio-toxicity) 
Resource use 
assumption 
Four GP visits are required during maintenance period of 6 months in 
order to prevent relapse 
Discounting No discounting, due to <1 year time horizon 
Maintenance Continue treatment for 6 months after remission, to prevent recurrence 
                                                   
 
 
 
 
10 Moore et al 2005 
11 Mean dose increase in the study that compared efficacy of the flexible doses of citalopram and escitalopram. 
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drop out 
symptoms reduced
symptoms reduced
symptoms persist
outpatient care
symptoms reduced
symptoms persist
inpatient care
secondary caresymptoms persist
switch to SNRI
symptoms reduced 
symptoms reduced
symptoms persist
outpatient care
symptoms reduced
symptoms persist
inpatient care
secondary caresymptoms persist
increase dose
no response 
symptoms reduced
symptoms persist
outpatient care
symptoms reduced
symptoms persist
inpatient care
secondary carediscontinuation
symptoms reduced
symptoms reduced
symptoms persist
outpatient care
symptoms reduced
symptoms persist
inpatient care
secondary caresymptoms persist
switch to SNRI
very strong AE
symptoms reduced
symptoms reduced
symptoms persist
outpatient care
symptoms reduced
symptoms persist
inpatient care
secondary caresymptoms persist
continue treatmentgood response*
Citalopr 20 mg
Escitalopr 10 mg
 [+] 
MDD (DSM-IV) 
 
week 0                  week 8                       week 12                        week 16        Week 24 
 
Figure 7: The model structure12. (Tree Age Pro Healthcare Module 2005).13
                                                   
12 The structure of the escitalopram node is identical as a citalopram node, with different probabilities.  
13 §=out of 1/2 patients that have some kind of AE, 10-20 % will have so strong AE that will lead to change in treatment strategy. *=symptom reduction >=50% 
MADRS score, from the baseline to week 8.  
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2.2. Measure of effectiveness  
 
Effectiveness data were collected from the review of the relevant literature (see Appendix I, 
search results). In the 24-week head-to-head trial of citalopram and escitalopram, patient at 
the baseline had MADRS score ≥22 and <40. The remission rate is defined as MADRS score 
≤12 measured at week 24 (Colonna, Andersen et al. 2005). In this model, remitter has the 
symptoms reduced outcome. Value of one (1) was assigned to this outcome. Patients who do 
have MADRS score greater than 12 have a symptoms persist outcome, with assigned value 
zero (0). In these patients, symptoms of the depression are still present after six months. The 
assumption is that 20 percent of the patients from the secondary care will not have symptom 
reduction after the six-month treatment. If this depression continues for another year and a 
half, patient has a chronic depression. In order to avoid relapse, patients that have symptom 
reduction should continue with the same treatment for the next six months and visit GP four 
times (maintenance therapy). An example of the MADRS instrument is in Appendix IV.  
 
2.3. Probabilities 
 
The review process aimed at collecting effectiveness data was performed through developing 
a search filter (MeSH term index database) and searching procedure that included RCTs 
(randomized controlled trials), systematic reviews (meta-analysis), economic evaluations and 
head-to-head trials on citalopram and escitalopram. Out of selected studies, inputs for a model 
are chosen based on quality of the studies. (Table 3, page 30). Inclusion criteria were RCT on 
efficacy, safety, effectiveness and/or tolerability of citalopram and escitalopram. Literature on 
effectiveness data was searched from October 2006. Studies that were rated as poor quality in 
systematic overviews were excluded. Databases searched were BMJ Clinical Evidence, The 
Cochrane Library, DARE (Database of Abstracts and Reviews of Effects), Centre for 
Reviews and Dissemination Databases, NHS EE Database (National Health System 
Economic Evaluation Database), HTA Database, CCOHTA (Canadian Coordinating Office 
for HTA), EMBASE, PsycINFO, SBU (The Swedish Council on Technology Assessment in 
Health Care), Oregon Evidence Based Practice Centre, PubMed.14   
 
                                                   
14 All databases can be found on the www.helsebiblioteket.no  
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A selection of the clinical evidence for model inputs 
 
Findings from the Oregon Evidence-based Practice Centre in general favoured escitalopram 
over citalopram. (Gartlehner, Carey et al. 2006) Two studies reported statistically 
significantly higher response rates for escitalopram than for citalopram (76.1% vs. 61.3%, 
p<0.05 and 63.7% vs. 52.6%; p =0.02115). In both studies, escitalopram also led to higher 
remission rates than citalopram.  
 
One trial was a fair-rated European/Canadian flexible dose study that compared the efficacy 
and tolerability of citalopram (20-40 mg/d) to escitalopram (10-20 mg/d) and placebo in 471 
depressed outpatients attending primary care centres. (Lepola, Loft et al. 2003) ITT results 
showed that the escitalopram group had significantly more responders16 (63.7% vs. 52.6%; p 
= 0.021) and remitters17 (52.1% vs. 42.8%; p<0.036) than the citalopram group. Escitalopram 
was numerically (not statistically) better on three efficacy scales (MADRS, CGI-I, CGI-S).  
 
The fourth study was a good fixed dose trial (escitalopram 10mg/d, citalopram 20 mg/d) in 
357 European primary care patients over 24 weeks. Escitalopram patients had significantly 
higher response rates at week 8 (63% vs. 55%; p<0.05) but not at week 24 (80% vs. 78%; 
p=NR). (Colonna, Andersen et al. 2005) A pooled analysis of data from three RCTs 
concluded that escitalopram significantly improved sleep disturbance compared to citalopram. 
(Lader, Andersen et al. 2005) 
 
There has been a lack of follow-up studies beyond six months. RCTs on citalopram and 
escitalopram lasted from four to 12 weeks. Only one good quality study lasted for 24 weeks 
(6 months).18 Many adverse effects (including suicide) may occur after this period. More 
RCTs in the future and reports from patients about drug toleration may show some adverse 
effects that are yet unknown.  
 
 
 
 
                                                   
15 Results are for escitalopram vs citalopram 
16 Responder is a patient that has a ≥ 50% reduction in MADRS score at week 8, from the baseline 
17 Remitter is patient that has MADRS score <12  
18 Colonna et al 2005 
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Table 3 Fair/good quality randomized controlled trials for citalopram and escitalopram 
 
Author/year N/ w19 Results Quality20 Health outcome  
measurement 
 
Source
(Burke, 
Gergel et al. 
2002) 
491/8 No sign. differ. 
between cital and 
escit.  
Fair MADRS, HAM-D, CGI-
S, HAM-A, CES-D, 
QOL. Mean change in 
score from baseline to 
week 8. 
21
22
(Colonna, 
Andersen et 
al. 2005)23
357/24 More responders 
remitters in esc group 
at 8 
weeks (but not at 
week 24) 
Good Mean change in MADRS 
score from baseline to 
week 24 Additional: 
CGIs and HAMa 
18 
(Lader, 
Andersen et 
al. 2005)  
1321/8 No sign diff in mean 
MADRS score. 
Fair MADRS (cital, escit, 
placebo) 
18 
(Lepola, Loft 
et al. 2003) 
471/8 Sign. More resp and 
remit in the escital 
group 
Esc>Pla 
Cit=Pla 
Fair Mean change in MADRS, 
CGI-S, CGI-I. Baseline, 
weeks 1,2,3,4,6,8 
18,19  
(Moore, 
Verdoux et al. 
2005) 
280/8 Sign. more 
responders and 
remitters in the 
escitalopram group 
Fair MADRS, CGI-S score. 
Baseline and weeks 1,4,8. 
18 
 
All trials were limited to male and female outpatients aged <65 years who met DSM-IV 
criteria for a first episode of a major depressive disorder, and had a MADRS score ≥22. Trial 
by Colonna included 357 adult patients, all aged <65 years. (Colonna, Andersen et al. 2005) 
This might mean violation of generalisability since aging population (especially in Norway) 
represents large group of antidepressants users.  
 
The probabilities for the model in this analysis where adopted from trial by Colonna (no 
response, drop out due to adverse effects, adverse effects, good response). Despite of 
limitations, this trial was the only one with good quality rating (meta-analysis by Oregon 
group), had the longest duration of 24 weeks and large number of patients (n=357). In 
addition, patients were from the seven European countries including Norway, and that may 
favour internal and external generalisability of the results. The main outcome measure 
                                                   
19 N= number of patients in the trial. w=nr of weeks of the clinical trial 
20 Quality rating as given in systematic overview, footnote 18.  
21 Åsberg M et al. 2004 
22 Gartlehner G et al. 2006 
23 Probabilities for the model are choosed from this trial
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(MADRS score at baseline and week 24) was not significantly different between escitalopram 
and citalopram. In the model, same main outcome measure was used.  
Table 4      Probabilities used in the analysis  
PROBABILITY* CIT ESCIT REFERENCE 
No response (at week 8)  0.45 0.37 (Colonna, Andersen et al. 2005) 
Drop out (AE) 0.10 0.06 (Colonna, Andersen et al. 2005) 
Adverse effects 0.1424 0.1325 (Colonna, Andersen et al. 2005) 
Good response26 0.31 0.44 Footnote 12 
Discontin. due to AE 0.3 0.3 Expert opinion 
Sympt.red. after discontin. 0.7 0.7 Footnote 13 
Sympt.pers after discontin. 0.3 0.3 (Wade, Toumi et al. 2005)27
Switch after strong AE 0.7 0.7 Expert opinion 
Sympt. red after switch28 0.45 0.45 (Posternak, Zimmerman et al. 2001) 
Sympt. persist after switch 0.55 0.55 (Posternak, Zimmerman et al. 2001) 
Inpatient care (hospit.)  0.1 0.1 Expert opinion29
Outpatient care 0.9 0.9 Expert opinion 
Sympt.red. after oupatient 0.8 0.8 (Hale 1997) 
Sympt.persist after outpat. 0.2 0.2 (Hale 1997)30
Sympt.red. after inpatient 0.8 0.8 (Hale 1997) 
Sympt.per. after outpatient 0.2 0.2 (Hale 1997) 
Sympt.red.after good resp. 0.6 0.6 Expert opinion (footnote 30) 
Sympt.per. after good resp.  0.4 0.4 Expert opinion31
Sympt.red.after dose incr. 0.43 0.52 (Lepola, Loft et al. 2003) 
(Lepola, Loft et al. 2003) Sympt.pers. after increa. 0.57 0.48 
 
*Lower and upper limit used for the sensitivity analysis of the parameters are in the Appendix III.   
                                                   
24 Assumption: 1/5 of patients that have any of the AE will change/discontinue treatment. Cital.group 72%(any AE)*20%(1/5)=14.4=0.14 
25 Escit. group 62.9%(any AE)*20%(1/5)=12.58= 0.13 
26 (0.45+0.10+0.14=0.69) than 0.31 is left for good response. Same method used for escitalopram.  
27 Rate used in this study was 27.5. Expert agreed on 0.3 as realistic rate. 
28 44.7% of patients had positive response after switching (Posternak&Zimmerman 2001, table 4).100-44,7=55.3% will not have remission after switched drug  
29 10% of the patient with depression will be hospitalized due to self-harm or suicidal thoughts or intentions. Same assumption was used in Wade et al 2005 
30 20% of patients will develop chronic depression 
31 This is called a rebound effect (patient going to improvement due to placebo and back to symptoms). 40% of the patients will  have a significant return of the 
original symptom(even after having good response to drug in the first 8-12 weeks)
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Table 5 Resources used in the model with the range for sensitivity analysis 
 
UNIT L32 U33 REFERENCE PARAMETER 
Frequency of specialist consult. when patient is hospital. 6 3 9 assumption 
Frequency of GP visits during maintenance 4 1 6 guidelines 
Frequency of GP visits when symptoms are reduced 2 1 4 guidelines 
Frequency of GP visits when symptoms persist 4 2 8 guidelines 
Frequency of specialist visits when symptoms are reduced 2 1 3 assumption 
Number of days on afipram (against nausea) 14 7 30 assumption 
 
 
2.4. Costs  
 
The costing process in economic evaluation has three phases: identification of resources (costs) 
that are related to the health care program and for the perspective taken, measurement of resource 
use (quantities of resources required for each of comparators in analysis, or frequency of use) and 
the cost valuation phase (assigning prices for identified and measured resources).  
 
In the cost identification phase, costs relevant to the health care payer and a societal perspective of 
both alternatives are identified. To identify costs it was necessary to assess which health care 
services/products depressive patients used (through the six months, and during maintenance phase 
if symptoms were reduced), in both primary and secondary care. For the health care payer 
perspective, these costs included diagnostic procedures, GP consultations, specialist consultations, 
inpatient care (hospitalization), drug costs, outpatient care, and maintenance costs. Indirect costs 
arise from the patient’s inability to function normally and that result in a decrease in productivity.  
 
Along costs from the health care payer perspective, productivity costs (day lost from work due 
depression) are added into societal perspective, with different frequency for primary and a 
secondary care.  Cost data used in this model comes from primary data (average costs from the 
three Norwegian psychiatric hospitals)34 and from secondary data (SSB, Norwegian Medicince 
Agency, GP and specialist fee schedules 2006-2007)  
 
                                                   
32 Lower limit for the sensitivity analysis 
33 Upper limit for the sensitivity analysis 
34 These data will be published in the master thesis of Holman PA in 2007, University of Oslo  
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Table 6    Costs in NOK for 2006/2007, used in model for the Norwegian setting 
 
NOK L-U35  DESCRIPTION REFERENCE COST ITEM 
  414.5036 125-600 Dg and drug prescr. (NGPA 2006) First GP consult  
  379.5037 125-600 Primary care (NGPA 2006) GP consultation 
  416.0038 266-600 Secondary care (NGPA 2006) Specialists consult. 
      2.2439 1.79-2.6840 Daily defined dose Footnote 15 Citalopram 20mg 
      6.3541 5.08-7.62 Daily defined dose Footnote 16 Escitalopram 10mg 
      9.5842 7.66-11.49 Daily defined dose Footnote 15 SNRI 
Increased Cital dose       3.19 2.55-3.83 42,3% incr. for cital (Lepola, Loft et al. 2003) 
Increased Escit dose       8.89 7.11-10.67 40% incr. for escit (Lepola, Loft et al. 2003) 
  403.2043 322.6-483.8 44prevent new episode Footnote 15 Maintenance cit. 
1 143.0045 914.4-1371.6 Footnote 36 Footnote 15 Maintenance escit. 
1 724.4046 1379.2-2069.2 Footnote 36 Footnote 15 Maintenance SNRI 
   574.2047 459.36-689.04 Footnote 36 Footnote 21 Mainten.increas.cit. 
1 600.2048 1280.1-1920.24 Footnote 36 Footnote 22 Mainten.increas.esc. 
7 000 3000-8000 LDPS/TDPS/VDPS Footnote 23 Cost day hospit. 
27 253.0049 22000-35000 LDPS/TDPS/VDPS Footnote 23 Aver.year/ cost/pat 
        4.1050 3.28-4.92 Treat nausea Footnote 23 Afipram for AE 
      65.00 40-12551 Due to cardiotoxicity (NGPA 2006) ECG (before switch) 
Production loss52 1309.35-2164.9553   1 460.00 Aver./day/salary www.ssb.no, 2006 
                                                   
35 Lower and upper limit for the sensitivity analysis 
36 GP’s fee for prescribing drug added (takst 1h, page 16,GP fee schedule 2006/2007)  
37 81.50(1/4 of capit. fee) +125(first 15 min)+108(fee next 15 min)+65.00(spec.GP fee)=379.50 
38 266+150=416 
39 Costs of all drugs in analysis calculated on a regular basis of sales price for three largest Norwegian pharmacy chains Vitus Apotek, Apoteke 1 and Alliance 
Apoteket, for one DDD (e.g. citalopram 98 tbl/20 mg= 219/98=2.24). Asked for prices 28.3.-30.3.2007  
40 Lower and upper limit for the sensitivity analysis is +/-20% for the all drug prices 
41 10 mg= 6.35 (622.5/98 tbl). For details, see footnote nr 39.  
42 Venlafaxine (Efexor®) 75 mg DDD. NOK 938.50/98 tbl=9.58 
43 DDD citalopram=2.24*180=403.20 
44 6 months after symptoms reduction, maintanance to prevent new depressive episode 
45 DDD escitalopram=6.35*180=1143  
46 Venlafaxine DDD= 9.58*180 days= 1724.40 
47 Increased citalopram dose=3.19*180=574.20 
48 Increased escitalopram dose=8.89*180=1600.20 
49 Per Arne Holman, Lovisenberg Diakonnale Psychiatric Hospital, Oslo, interviewed 23.3.2007 
50 Afipram (metoklopramid) for nausea. NOK 68.10/50 tbl=1.362 per tbl*3 daily= NOK 4.086 per day  
51 NOK 40 from www.legemiddelverket.no/upload/28350/Publisert%20rapport%20-%20mars%202007.pdf
52 Nr of days lost from work at prim. care 7 days, sec care 15 days (average 11 days). Assumption based on the study by Lepine et al 1997 
53 Average monthly salary for industrial worker in Norway in 12/2006 was NOK 26187/20 days=NOK 1309.35 daily. For leaders, monthly salary was 
43299/20=NOK 2164.95 daily 
 33
2.5. Sensitivity analysis 
 
The robustness of the results was tested in the univariate sensitivity analysis on costs and 
probabilities and from the societal perspective. I have used two intervals. Lower and upper 
limits used in the sensitivity analysis are in Table 4 for probabilities, Table 5 for frequences of 
resources used and Table 6 for costs. Table with all parameters and lower and upper limits 
used in the model is in Appendix II (from Tree Age Pro). Table with results from the one-way 
sensitivity analysis are in the Appendix III.  
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3.  Results   
 
3.1. Health care payer perspective 
 
From the health care payer perspective, the average costs per patient in the escitalopram group 
was NOK 5171 while in the citalopram group this costs was NOK 3911. The incremental 
(additional) cost per patient treated with escitalopram was NOK 1260. In the escitalopram group  
it was expected that drug will be effective in 84.7% of the patients, while in the citalopram group 
it was expected to be effective in 80.0% of the patients. Thus, expected incremental effects was 
4.7%. When incremental costs are divided by incremental effects, result is expressed in term of 
the incremental cost-effectiveness ratio (ICER).  
 
27035
0466.0
8.1259 ==Δ
Δ=
E
CICER  
 
From a health care payer perspective, the cost per additional patient with reduced symptoms was 
NOK 27035 when citalopram was replaced by escitalopram.  
 
Table 7 Results for the health care payer perspective 
Strategy Cost54 Incr 
Cost55
Eff Incr Eff C/E ICER 
Citalopr 20 mg 3 911  0.801  4 881  
Escitalopr 10 mg 5 171 1 259 0.848 0.047 6 098 27 035 
        
TABLE 2 - all options refer. 
to a common baseline 
      
Citalopr 20 mg 3 911  0.801  4 881  
Escitalopr 10 mg 5 171 1 259 0.848 0.047 6 098  
        
TABLE 3 - ordered by 
increasing effectiveness 
      
Citalopr 20 mg 3 911  0.801  4 881  
Escitalopr 10 mg 5 171  0.848  6 098  
 
 
 
 
 
                                                   
 
55 Incremental costs in NOK 
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Cost-Effectiveness Analysis
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Figure 8 Cost-effectiveness of replacing citalopram by escitalopram. Health care payer 
perspective. No strategy is clearly dominated by other (because escitalopram is more costly 
and more expensive). 56
 
3.2. Societal perspective 
 
From the societal perspective, the expected average costs for one patient in the escitalopram group 
was NOK 20 561 while in citalopram group this costs was NOK 19 695. The incremental 
(additional) cost per treated patient with escitalopram was NOK 865. Expected effectiveness was 
the same as in the health care payer perspective, but the costs have changed; in the escitalopram 
group it is expected that drug will be effective in 84.7% of the patients, while in the citalopram 
group it was expected to be effective in 80% of the patients. As a result, incremental effects are 
4.7%. When incremental costs are divided by incremental effects, the result is expressed in terms 
of the incremental cost-effectiveness ratio (ICER).  
 
18575
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From a societal perspective, the cost per additional patient with reduced symptoms was  
NOK 18 575 when citalopram was replaced by escitalopram.  
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Table 8 Results for the societal perspective 
 
Strategy Cost Incr.costs 
(NOK) 
Effect. Incr 
Eff 
C/E ICER 
Citalopr 20 mg 19 695  0.801  24 578  
Escitalopr 10 mg 20 561 866 0.848 0.047 24 248 18 575
       
TABLE 2 - all options ref. 
to a common baseline 
      
Citalopr 20 mg 19 696  0.801  24 578  
Escitalopr 10 mg 20 561 866 0.848 0.047 24 248  
       
TABLE 3 - ordered by 
increasing effectiveness 
      
Citalopr 20 mg 19 696  0.801  24 578  
Escitalopr 10 mg 20 561  0.848  24 248  
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Figure 9 Cost-effectiveness of replacing citalopram by escitalopram. Societal perspective.  
 
 
 
 
 
 
 
                                                                                                                                                               
56 An option is dominated if it is more costly and less effective than comparator. 
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3.3. Cost-utility analysis 
 
Cost-utility analysis is a useful technique because it provides a generic outcome measurement 
which enables comparison of the costs and health outcomes across different health care 
programmes. In order to express results of my analysis in terms of cost per QALY gained, I 
have used utility weights for the major depressive disorder from three different studies. 
(Mauskopf and Simon 2006)   
 
Table 9  Studies with the utility weights for MDD, from the meta-analysis by Mauskopf  
 
AUTHOR METHOD N TIME BASE U  ∆IN U 
REMISSION 
∆ IN U NO 
RESPONSE 
Lanert et al 200057 SG 140 1 year - 0.042 -0.012 
(Sapin, Fantino et al. 2004) EQ-5D 250 2 m. 0.3-0.35 0.5 0.28 
(Pyne, Sieber et al. 2003) QWB-SA 4 m. 0.41-0.425 0.201 0.021 58 
 
In my model, the treatment benefit is expressed in terms of “successfully treated depression” 
(symptoms reduced) after a 6-month period. On the basis of the study by Pyne, Sieber et al 
2003, I assume that the average difference in utility between successful and unsuccessful 
treatment is 0.2258. This means that the QALY gain from successful treatment is 
0.22*0.5=0.11; due to half a year time perspective of my study. Consequently, cost per 
QALY gained for the health care payer perspective is NOK 245 000.59 Using the same 
methodology and assumption, cost per QALY gained for the societal perspective is NOK 
169 000.60 If NOK 350 000 were chosen as the cost-effectiveness threshold, escitalopram is 
cost-effective.   
 
 
 
 
 
 
                                                   
57 Lanert has not reported baseline utility, therefore I have not used utility weights from his study.  
58 0.5-0.28=0.22 
59 ICER for health care payer perspective is NOK 27000/0.11= NOK 245 454 
60 ICER for societal perspective is NOK 18600/0.11=NOK 169000 
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Using the value 0.1861 for the average difference in utility between successful and 
unsuccessful treatment based on the study by Sapin et al 2004, QALY gain from successful 
treatment is 0.18*0.5=0.09; due to half a year time perspective of my study.  
Thus, cost per QALY gained for the health care payer perspective is NOK 300 000.62 For the 
societal perspective, cost per QALY gained is NOK 207 000. 63 Escitalopram is cost-
effective.  
 
Using utilities from the study by Lanert et al 2000 under the assumption that the average 
difference in utility between successful and unsuccessful treatment is 0.054*0.5=0.027 is the 
QALY gain from the successful treatment due to 6-month time of my study, cost per QALY 
gained is NOK 1000 000 for the health care payer perspective.64 Thus, for the societal 
perspective, under the same assumptions and using the same methodology, cost per QALY 
gained is NOK 690 000. Escitalopram is not cost-effective.  
 
Table 10  Results of the cost-utility analysis 
REFERENCE INSTRUMENT
65
QALYS 
GAIN66  
COST PER QALY,  
SOCIETAL 
PERSPECTIVE  
COST PER QALY, 
HEALTH CARE PAYER 
PERSPECTIVE  
COST-EFF. OF ESCIT 
IF TRESHOLD IS  
NOK 35000067
Pyne et al 
2003 
QWB-SA 0.11 169 000    245 000 Yes 
Sapin et al 
2004 
EQ-5D 0.09 207 000    300 000 Yes 
Lanert SG 0.027 690 000 1 000 000 No 
Difference68 - 0.083 521 000    755 000 - 
    
The results in terms of costs per QALY gained depend on utility gain from the successful 
treatment. Hence these utilities depend on the instrument used. The study by Pyne assessed 
utility weights at four months by the quality of well-being scale (QWB-SA).  
 
                                                   
61 0.201-0.021=0.18 
62 27000/0.09=300 000 
63 18600/0.09=206 666 
64 ICER 27000/0.027=1000 000 
65 Instrument used to assess utility weights for depression 
66 QALYs gain from succesful treatment,  as difference from the change in utility when remission- change in utility when  no response 
67 Kristiansen, I. S., D. Gyrd-Hansen, et al. (2007). "[Prioritization and health--should maximum-price life years be introduced?]." Tidsskrift for Den Norske 
Laegeforening 127(1): 54-7. 
 
68 Difference between the lowest to the highest utility value 
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When these utility weights were used in my analysis, cost per QALY gained was NOK 
169 000 for the societal perspective and NOK 245 000 for the health care payer perspective. 
Escitalopram is a cost-effective option.  
 
Study by Sapin used EQ-5D (quality of life five-dimension instrument) which tend to 
overestimate utilities. Cost per QALY gained using Sapin’s utility weights was NOK 207 000 
for the societal and NOK 300 000 for the health care payer perspective. Escitalopram is a 
cost-effective option.  
 
Lanert have used the standard gamble method,  which has resulted in the lowest utility values 
after one year when compare to other two studies by Pyne and Sapin. Consequenlty, the 
lowest change in the utility weights led to the highest cost per QALY gained of NOK 690 000 
for the societal and NOK 1 000 000 for the health care payer perspective. Considering the  
treshold for cost per QALY gained which is NOK 350 000 in Norway, escitalopram is not a 
cost-effective option over citalopram. 
 
I have decided to use results based on the utility change by from the study Pyne, because of  
advantages of that study compared to Sapin and Lanert: choice of the instrument was Self-
Administered Quality of Well-being Scale (QWB-SA) which does not overestimate utility 
weights as EQ-5D does and study duration was four months, which is reasonable since my 
model has a time of six months. It is remarkable that cost per QALY gained among the three 
scenarios differ for about NOK 500 000 in the societal perspective and even NOK 755 000 in 
the health care payer perspective.69 This emphasizes the importance of the instrument choice 
in collecting utility weights.  
 
 
 
 
 
 
 
 
                                                   
69 Difference between the lowest to the highest utility value
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3.3. Sensitivity analysis results 
 
In one-way sensitivity analyses on all parameters (costs and probabilities), the results were, in 
the societal perspective, robust for all the parameters except for the  probability of a good 
response in the escitalopram group. This parameter had value of 0.44 with lower bound of 
0.39 and upper limit of 0.49. When lower bound (0.39) was used for good response rate in 
escitalopram group, this affected results so that escitalopram was not cost-effective any longer 
but it was dominated by citalopram. (Appendix III) 
 
The results were not sensitive to changes in the unit costs. Largest variation in ICER appeared 
at probability of no response to citalopram at week 8. Here the difference between lower and 
upper ICER was NOK 230 000.  
 
Changes in assumptions about productivity costs (where the  assumptions for lower and upper 
limit were based on the average number of working days lost due to depression in six-month 
period) resulted in variation in ICER of NOK 8 400 for the primary care patients and NOK 
19 000 for the secondary care patients.   
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4. Discussion 
 
The results of the cost-utility analysis suggest that escitalopram is cost-effective in treating 
major depressive disorder in Norway. CUA resulted in the cost per QALY gained of NOK 
169 000 for the societal and NOK 245 000 for the health care payer perspective. For both 
perspectives cost per QALY gained was under the threshold of NOK 350 000.  
 
The utility gain from depression treatment of 0.11 that I used in this study might not be the 
best estimate of utility gain for depressed patients treated with citalopram and escitalopram. 
The study by Pyne assessed utility weights from relativelly small number of patients (n=58). 
Therefore my conclusions which are based on these utilities should be taken with caution.   
 
Study limitations  
 
Limitations in the studies occurs due to complexity of the pharmacoeconomics and a lack of a 
generally accepted methodology. (Pirraglia, B. et al. 2004) There has been lack of guideliness 
for economic evaluation in Norway and there is no consensus among analysts as to what 
should be included in the analysis. In addition, there is no standardized cost database for 
Norway.  
 
Another limitation comes from the use of the RCTs as the source of the effectiveness data. 
When pharmaceutical companies fund RCT they avoid to enroll patients with severe 
depression because to have mildly/moderately depressed patients in trial might result in better 
effectiveness of the new drug. Around one third of patients in the trials fail to complete the 
trial so it seems that only patients to whom the drug works remain in the trial and the number 
of serious adverse events might be underestimated. Besides the short duration of clinical trials 
on citalopram and escitalopram, RCTs did not measured utilities so I had to tranfer utility 
weights into QALYs.  
The main limitation of my model is a six-month time perspective. Cost-effectiveness of the 
treatment of MDD depends on the success of the treatment in the long run while RCT on 
citalopram and escitalopram show efficacy in the short period (mostly for only eight and 14 
weeks, only one trial lasted for 24-weeks). The 24-week head-to-head clinical trial of 
citalopram and escitalopram used in my model included 357 adults that were under age of 65. 
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(Colonna, Andersen et al. 2005) This is also limitation since an aging population in Norway 
represents a large group of patients that use citalopram and escitalopram.  
 
In the societal perspective I have used productivity costs based on average days that employed 
persons loses from work due to depression. In order to capture broader societal costs, analysis 
can use e.g. travel costs and costs of time lost by the depressed person’s family members. 
These costs are not included in my analysis.  
  
Reviews of the literature that I have used to assess effectiveness data did not validate the 
quality of each of the reviewed studies. One-way sensitivity analyses is performed; changing 
one variable at a time  is not realistic but it gives us an idea of which of the model parameters 
might have the strongest influence on results.     
 
Strengths of the study  
 
This study was not funded by anyone and the author did not have any interest in presenting 
any of drugs as cost-effective. I have used cost data for 2006-2007 and empirical data for 
average yearly costs per patient at the psychiatric hospital in Oslo.  
 
The model has some improvements when compared to some previous ones, and some 
limitations as well. Other models were separated primary and secondary care. Because the 
patient begins in the primary care and goes to secondary, in many cases he will go back and 
forth as depression changes. Therefore I see a strict distinction between primary and 
secondary care as unnecessary. Further, published CEA on citalopram vs. escitalopram lack 
the comparative clinical data between two drugs. (e.g. Francois et al 2003) 
 
In calculating productivity loss, other studies have used assumptions that all patients work. 
Productivity costs in my study were based on the average loss of working days during six 
months for depressed person. Using utility weights and expressing results in cost per QALY  it 
is possible to compare results to other analyses.   
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Comparison with other cost-effectiveness studies 
 
Comparing my results with the other CEA that analysed cost-effectiveness of citalopram and 
escitalopram, the conclusion that escitalopram is cost-effective does not differ. All studies 
(Table 11) were funded by Lundbeck. In the  study by Kulp from 2005 it is not clear whether 
study is funded and by whom. Kulp has used a Markov model while other studies used a two-
path decision tree.   
 
Table 11 Other cost-effectiveness studies results 
 
REFERENCE COUNTRY COMPARATORS ANALYSIS/MODEL/ 
PERSPECTIVE 
CONCLUSION 
(Demyttenaere, 
Hemels et al. 2005) 
Belgium escitalopram,citalopram, 
venlafaxine 
CEA/decision tree Escitalopram is cost-
effective 
(Francois, Toumi et 
al. 2003) 
Norway escitalopram,citalopram, 
fluoxetine,venlafaxine 
CEA/decision tree Escitalopram is cost-
effective. 
(Kulp, von der 
Schulenburg et al. 
2005) 
Germany  
escitalopram, venlafaxine 
CEA/markov model 
(70 days) 
Escitalopram is 
“preferable” to 
venlafaxine 
(Hemels, Kasper et 
al. 2004) 
Austria escitalopram, vs. 
citalopram 
CEA/decision tree Escitalopram is cost-
effective from the 
societal perspective 
(Wade, Toumi et al. 
2005) 
UK  CEA/decision tree Escitalopram is cost-
effective compared to  
citalopram but not 
compared to venlafaxine 
escitalopram,venlafaxine, 
citalopram 
 
 
Policy implications 
 
Based on this analysis society should fund escitalopram for treatment of depression in 
Norwegian adults as it appeared cost-effective from societal and health care payer 
perspective. Although the price of escitalopram is relatively high, cost savings compensate for 
the drug price, especially in societal perspective.  
 
Escitalopram should not be seen as expensive for society because it might improve patients’ 
quality of life, increase their social functioning and ability to work. Analysis results indicate 
the need for increasing the daily defined dose of citalopram 20 mg and escitalopram 10 mg. 
Sufficient dose at the beginning of the treatment might save costs later. It might be useful  to 
re-evaluate daily defined doses for citalopram and escitalopram. Costs of an increased dose of 
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the drug might be lower than costs of increased resource use caused by an insufficient 
minimal daily dose.  
 
The results of this decision analysis indicate that three types of data are needed to reduce the 
uncertainty about the cost-effectiveness of escitalopram. First we need trials of 1-5 years of 
follow-up because depression is a chronic disease. Such trials would provide more accurate 
data on the probabilities of the model. Second, we need data on quality of life captured in a 
long-term trial, preferably with the TTO or a similar method. This would provide better data 
on utilities for different depression health states. Third, we need more data on how patients in 
practice are treated for major depression in Norway.  
 
The results demonstrate that escitalopram is likely to be a cost-effective option in the short-
run. Based on my analysis I do not have evidence to draw conclusions about the long-run 
cost-effectiveness of escitalopram (1-5 years). 
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Appendix I Rolled-back tree   
Expected values, citalopram node, health care payer perspective    
 
 
drop out 
0,10 481,70kr / 0
symptoms reduced
0,45 5 385,40kr / 1
symptoms reduced
0,80
6 217,40kr / 1
symptoms persist
0,20 2 170,25kr / 0
outpatient care
0,90 5 407,97kr / 1
symptoms reduced
0,80 21 881,40kr / 1
symptoms persist
0,20 2 549,75kr / 0
inpatient care
0,10 18 015,07kr / 1
secondary care
6 668,68kr / 1
symptoms persist
0,55 secondary care : 6 6 8, kr / 1
switch to SNRI
6 091,20kr / 1
symptoms reduced 
0,43 3 403,40kr / 1
symptoms reduced
0,80 4 614,90kr / 1
symptoms persist
0,20 1 717,95kr / 0
outpatient care
0,90
4 035,51kr / 1
symptoms reduced
0,80
20 278,90kr / 1
symptoms persist
0,20 1 717,95kr / 0
inpatient care
0,10 16 566,71kr / 1
secondary care
5 288,63kr / 1
symptoms persist
0,57 secondary care : 5 288,63kr / 1
increase dose
4 477,98kr / 1
no response 
0,45 increase dose : 4 477,98kr / 1
symptoms reduced
0,70 1 760,40kr / 1
symptoms persist
0,30 955,65kr / 0
outpatient care
0,90 1 518,98kr / 1
symptoms reduced
0,90 18 183,40kr / 1
symptoms persist
0,10 955,65kr / 0
inpatient care
0,10 16 460,63kr / 1
secondary care
3 013,14kr / 1
discontinuation
0,30 secondary care : 3 013,14kr / 
symptoms reduced
0,45 5 442,80kr / 1
symptoms reduced
0,80 6 274,80kr / 1
symptoms persist
0,20
2 607,15kr / 0
outpatient care
0,90 5 541,27kr / 1
symptoms reduced
0,80 22 318,30kr / 1
symptoms persist
0,20 2 607,15kr / 0
inpatient care
0,10
18 376,07kr / 1
secondary care
6 824,75kr / 1
symptoms persist
0,55 secondary care : 6 824,75kr / 1
switch to SNRI
0,70 6 202,87kr / 1
very strong AE
0,14 5 245,95kr / 1
symptoms reduced
0,60
2 738,90kr / 1
symptoms reduced
0,80 3 950,40kr / 1
symptoms persist
0,20 1 603,95kr / 0
outpatient care
0,90
3 481,11kr / 1
symptoms reduced
0,80 17 950,40kr / 1
symptoms persist
0,20 15 224,45kr / 0
inpatient care
0,10 17 405,21kr / 1
secondary care
4 873,52kr / 1
symptoms persist
0,40 secondary care : 4 873,52kr / 1
continue treatment
3 592,75kr / 1
good response*
0,31 continue treatment : 3 592,75kr / 1
Citalopr 20 mg
3 911,45kr / 1
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Expected values, escitalopram node, health care payer perspective  
 
 
drop out 
0,06 605,00kr / 0
symptoms reduced
0,45 5 317,35kr / 1
symptoms reduced
0,80 6 464,00kr / 1
symptoms persist
0,20
2 416,85kr / 0
outpatient care
0,90 5 654,57kr / 1
symptoms reduced
0,80 22 128,00kr / 1
symptoms persist
0,20 2 796,35kr / 0
inpatient care
0,10
18 261,67kr / 1
secondary care
6 915,28kr / 1
symptoms persist
0,55 secondary care : 6 915,28kr / 1
switch to SNRI
6 196,21kr / 1
symptoms reduced
0,52
5 360,00kr / 1
symptoms reduced
0,80 6 571,50kr / 1
symptoms persist
0,20 2 648,55kr / 0
outpatient care
0,90 5 786,91kr / 1
symptoms reduced
0,80 22 235,50kr / 1
symptoms persist
0,20 2 648,55kr / 0
inpatient care
0,10 18 318,11kr / 1
secondary care
7 040,03kr / 1
symptoms persist
0,48 secondary care : 7 040,03kr / 1
increase dose
6 166,41kr / 1
no response
0,37 increase dose : 6 166,41kr / 1
symptoms reduced
0,70 2 007,00kr / 1
symptoms persist
0,30 1 202,25kr / 0
outpatient care
0,90
1 765,58kr / 1
symptoms reduced
0,80
18 430,00kr / 1
symptoms persist
0,20 1 202,25kr / 0
inpatient care
0,10 14 984,45kr / 1
secondary care
3 087,46kr / 1
discontinuation
0,30 secondary care : 3 087,46kr / 1
symptoms reduced
0,45 5 689,40kr / 1
symptoms reduced
0,80
6 521,40kr / 1
symptoms persist
0,20 2 853,75kr / 0
outpatient care
0,90 5 787,87kr / 1
symptoms reduced
0,80 22 564,90kr / 1
symptoms persist
0,20 2 853,75kr / 0
inpatient care
0,10 18 622,67kr / 1
secondary care
7 071,35kr / 1
symptoms persist
0,55
secondary care : 7 0 1,35kr / 1
switch to SNRI
0,70 6 449,47kr / 1
very strong AE§
0,13
5 440,87kr / 1
symptoms reduced
0,60 4 218,50kr / 1
symptoms reduced
0,80 5 430,00kr / 1
symptoms persist
0,20 2 343,75kr / 0
outpatient care
0,90 4 812,75kr / 1
symptoms reduced
0,80 18 690,20kr / 1
symptoms persist
0,20
1 964,25kr / 0
inpatient care
0,10 15 345,01kr / 1
secondary care
5 865,98kr / 1
symptoms persist
0,40 secondary care : 5 865,98kr / 1
continue treatment
4 877,49kr / 1
good response*
0,44 continue treatment : 4 877,49kr / 1
Escitalopr 10 mg
5 171,28kr / 1
 
 
 
 54
Expected values, citalopram node, societal perspective 
drop out 
0,10 10 701,70kr / 0
symptoms reduced
0,45 15 605,40kr / 1
symptoms reduced
0,80
28 117,40kr / 1
symptoms persist
0,20 24 070,25kr / 0
outpatient care
0,90 27 307,97kr / 1
symptoms reduced
0,80 43 781,40kr / 1
symptoms persist
0,20 24 449,75kr / 0
inpatient care
0,10 39 915,07kr / 1
secondary care
28 568,68kr / 1
symptoms persist
0,55 secondary care : 28 568, kr / 1
switch to SNRI
22 735,20kr / 1
symptoms reduced 
0,43 13 623,40kr / 1
symptoms reduced
0,80 26 514,90kr / 1
symptoms persist
0,20 23 617,95kr / 0
outpatient care
0,90
25 935,51kr / 1
symptoms reduced
0,80
42 178,90kr / 1
symptoms persist
0,20 23 617,95kr / 0
inpatient care
0,10 38 466,71kr / 1
secondary care
27 188,63kr / 1
symptoms persist
0,57 secondary care : 27 188,63kr / 1
increase dose
21 355,58kr / 1
no response 
0,45 increase dose : 21 355,58kr / 1
symptoms reduced
0,70 23 660,40kr / 1
symptoms persist
0,30 22 855,65kr / 0
outpatient care
0,90 23 418,98kr / 1
symptoms reduced
0,90 40 083,40kr / 1
symptoms persist
0,10 22 855,65kr / 0
inpatient care
0,10 38 360,63kr / 1
secondary care
24 913,14kr / 1
discontinuation
0,30 secondary care : 24 913,1 kr / 
symptoms reduced
0,45 15 662,80kr / 1
symptoms reduced
0,80 28 174,80kr / 1
symptoms persist
0,20
24 507,15kr / 0
outpatient care
0,90 27 441,27kr / 1
symptoms reduced
0,80 44 218,30kr / 1
symptoms persist
0,20 24 507,15kr / 0
inpatient care
0,10
40 276,07kr / 1
secondary care
28 724,75kr / 1
symptoms persist
0,55 secondary care : 28 724,75kr / 1
switch to SNRI
0,70 22 846,87kr / 1
very strong AE
0,14 23 466,75kr / 1
symptoms reduced
0,60
12 958,90kr / 1
symptoms reduced
0,80 25 850,40kr / 1
symptoms persist
0,20 23 503,95kr / 0
outpatient care
0,90
25 381,11kr / 1
symptoms reduced
0,80 39 850,40kr / 1
symptoms persist
0,20 37 124,45kr / 0
inpatient care
0,10 39 305,21kr / 1
secondary care
26 773,52kr / 1
symptoms persist
0,40 secondary care : 26 773,52kr / 1
continue treatment
18 484,75kr / 1
good response*
0,31 continue treatment : 18 4 4,75kr / 1
Citalopr 20 mg
19 695,80kr / 1
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Expected values, escitalopram node, societal perspective 
 
drop out 
0,06 10 825,00kr / 0
symptoms reduced
0,45 15 537,35kr / 1
symptoms reduced
0,80 28 364,00kr / 1
symptoms persist
0,20
24 316,85kr / 0
outpatient care
0,90 27 554,57kr / 1
symptoms reduced
0,80 44 028,00kr / 1
symptoms persist
0,20 24 696,35kr / 0
inpatient care
0,10
40 161,67kr / 1
secondary care
28 815,28kr / 1
symptoms persist
0,55 secondary care : 28 815,28kr / 1
switch to SNRI
22 840,21kr / 1
symptoms reduced
0,52
15 580,00kr / 1
symptoms reduced
0,80 28 471,50kr / 1
symptoms persist
0,20 24 548,55kr / 0
outpatient care
0,90 27 686,91kr / 1
symptoms reduced
0,80 44 135,50kr / 1
symptoms persist
0,20 24 548,55kr / 0
inpatient care
0,10 40 218,11kr / 1
secondary care
28 940,03kr / 1
symptoms persist
0,48 secondary care : 28 940,03kr / 1
increase dose
21 992,81kr / 1
no response
0,37 increase dose : 21 992,81kr / 1
symptoms reduced
0,70 23 907,00kr / 1
symptoms persist
0,30 23 102,25kr / 0
outpatient care
0,90
23 665,58kr / 1
symptoms reduced
0,80
40 330,00kr / 1
symptoms persist
0,20 23 102,25kr / 0
inpatient care
0,10 36 884,45kr / 1
secondary care
24 987,46kr / 1
discontinuation
0,30 secondary care : 24 987,46kr / 1
symptoms reduced
0,45 15 909,40kr / 1
symptoms reduced
0,80
28 421,40kr / 1
symptoms persist
0,20 24 753,75kr / 0
outpatient care
0,90 27 687,87kr / 1
symptoms reduced
0,80 44 464,90kr / 1
symptoms persist
0,20 24 753,75kr / 0
inpatient care
0,10 40 522,67kr / 1
secondary care
28 971,35kr / 1
symptoms persist
0,55
secondary care : 28 971,35kr / 1
switch to SNRI
0,70 23 093,47kr / 1
very strong AE§
0,13
23 661,67kr / 1
symptoms reduced
0,60 14 438,50kr / 1
symptoms reduced
0,80 27 330,00kr / 1
symptoms persist
0,20 24 243,75kr / 0
outpatient care
0,90 26 712,75kr / 1
symptoms reduced
0,80 40 590,20kr / 1
symptoms persist
0,20
23 864,25kr / 0
inpatient care
0,10 37 245,01kr / 1
secondary care
27 765,98kr / 1
symptoms persist
0,40 secondary care : 27 765,98kr / 1
continue treatment
19 769,49kr / 1
good response*
0,44 continue treatment : 19 769,4 kr / 1
Escitalopr 10 mg
20 561,43kr / 1
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Appendix II Parameters used in the model 
 
Health care payer perspective 
Parameters, values and lower and upper 
range       
Name Value Low High 
cAver_yr_patient_psychiatry 27,253 22000 35000
cDaily_afipram_for_side_eff 4,1 3,28 4,92
cDDD_cital_20mg 2,24 1,79 2,68
cDDD_escital_10mg 6,35 5,08 7,62
cDDD_SNRI 9,58 7,66 11,49
cECG_before_venlafaxine 65 40 125
cFirstGP_visit_diagnostics 414,5 125 600
cGP_visit 379,5 125 600
cInceras_escital14mg 8,89 7,11 10,67
cIncreas_cital_28mg 3,19 2,55 3,83
cSpecialist_consult 416 266 600
c_day_hospital 7000 3000 8000
c_Increas_SNRI_100mg 0     
c_maintenanceSNRI 1724,4 1379,2 2069,2
c_maintenance_cital 403,2 322,6 483,8
c_maintenance_escit 1143 914,4 1371,6
c_maintenance_increased_escit 1600,2 1280,1 1920,24
c_maintenance_increas_cital 574,2 459,36 689,04
fSpec_consul_when_hospitalization 6 3 9
f_GPvisits_during_maintenance 4 1 6
f_GPvisit_if_sympt_reduced 2 1 4
f_spec_consult_if_sympt_persist 4 2 8
f_spec_consult_if_sympt_reduced 2 1 3
nr_of_days_on_afipram 14 7 30
pdrop_out_cital 0,1 0,06888 0,13112
pdrop_out_escit 0,06 0,035364 0,084636
pgoodresponse_cital 0,31 0,262024 0,357976
pgoodresponse_escit 0,44 0,388508 0,491492
p_AEstrong_cital 0,14 0,104006 0,175994
p_AEstrong_escit 0,13 0,095114 0,164886
p_discontin_cit 0,3 0,252463 0,347537
p_discontin_escit 0,3 0,252463 0,347537
p_inpatient_cital 0,1 0,06888 0,13112
p_inpatient_escital 0,1 0,06888 0,13112
p_noresponse_cit 0,45 0,398393 0,501607
p_noresponse_escit 0,37 0,319917 0,420083
p_outpatient_second_care_cit 0,9 0,86888 0,93112
p_outpatient_second_care_escit 0,9 0,86888 0,93112
p_switch_after_strong_AE_cit 0,7 0,652463 0,747537
p_switch_after_strong_AE_escit 0,7 0,652463 0,747537
p_sympt_pers_after_discont_cit 0,3 0,252463 0,347537
p_sympt_pers_after_discont_escit 0,3 0,252463 0,347537
p_sympt_pers_after_goodresp_cit 0,4 0,349181 0,450819
p_sympt_pers_after_goodresp_escit 0,4 0,349181 0,450819
p_sympt_pers_after_increase_cit 0,57 0,518644 0,621356
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p_sympt_pers_after_increase_escit 0,48 0,428174 0,531826
p_sympt_pers_after_outpat_cit 0,2 0,158506 0,241494
p_sympt_pers_after_outpat_escit 0,2 0,158506 0,241494
p_sympt_pers_after_switch_cit 0,55 0,498393 0,601607
p_sympt_pers_after_switch_escit 0,55 0,498393 0,601607
p_sympt_red_after_discont_cit 0,7 0,652463 0,747537
p_sympt_red_after_discont_escit 0,7 0,652463 0,747537
p_sympt_red_after_goodresp_cit 0,6 0,549181 0,650819
p_sympt_red_after_goodresp_escit 0,6 0,549181 0,650819
p_sympt_red_after_increase_cit 0,43 0,378644 0,481356
p_sympt_red_after_increase_escit 0,52 0,468174 0,571826
p_sympt_red_after_inpat_cit 0,8 0,758506 0,841494
p_sympt_red_after_inpat_escit 0,8 0,758506 0,841494
p_sympt_red_after_outpat_cit 0,8 0,758506 0,841494
p_sympt_red_after_outpat_escit 0,8 0,758506 0,841494
p_sympt_red_after_switch_cit 0,45 0,398393 0,501607
p_sympt_red_after_switch_escit 0,45 0,398393 0,501607
qdays_cital_before_discontinuat 60 30 90
qdays_escit_before_discontinuat 60 30 90
qdays_on_cital_before_dropout 30 7 60
qdays_on_escit_before_dropout 30 7 60
q_days_good_resp_cital 180 60 360
q_days_good_resp_escit 180 60 360
q_days_on_cital_before_increase 60 30 90
q_days_on_escit_before_increase 60 30 90
q_days_on_switched_SNRI 120 60 160
q_of_days_in_hospital 2 1 7
q_of_days_on_cital_before_switch 60 30 80
q_of_days_on_escit_before_switch 60 30 80
q_of_days_on_increased_cital 120 40 180
q_of_days_on_increased_escit 120 40 180
 
Societal perspective 
 
q_workdays_lost_primarycare 7 2 10
q_workdays_lost_secondarycare 15 5 21
cProductDayFromWork 1460 1309,35 2164,95
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Appendix III One-way sensitivity analysis results 
 
Name Description Lower  Upper  
cAver_yr_patient_psychiatry average cost per pat yearly,3 psych hospit Oslo  15283 13343  
cDaily_afipram_for_side_eff daily cost of afipram   18566 18562 
cDDD_cital_20mg cost of 20 mg citalopram DDD  19465 17682  
cDDD_escital_10mg cost of DDD escitalopram,10 mg  15566 21562  
cDDD_SNRI DDD 75 mg venlafaxine (Efexor in Norway)  18598 18530 
cECG_before_venlafaxine due to cardiotoxicity of the drug  18568 18555 
cGP_visit cost for one GP visit in Norway  18090 18974 
cInceras_escital14mg dose can be increased to 20 mg daily  16883 20245  
cIncreas_cital_28mg 28 mg of citalopram cost  19300 17829  
cProductDayFromWork day that patient is out of job due to depression  19429 14516  
cSpecialist_consult consultation with specialist in psychiatry  18823 18247  
c_day_hospital inpatient care psychiatric clinic  19445 18345  
c_maintenanceSNRI if reduced sympt,continue therapy for 6 months  18610 18518  
c_maintenance_cital 6 months after symptom red,to prevent relapse  19029 18100 
c_maintenance_escit 6 months after symp red,to prevent relapse  16664 20463  
c_maintenance_increased_escit 6 months after sympt red, to prevent relapse  16287 20840 
c_maintenance_increas_cital 6 months maint on incr dose of citalopram  19299 17829 
fSpec_consul_when_hospitalization  Frequency of special consult if inpatient care  18746 18382 
f_GPvisits_during_maintenance during 6 months of maint. pat will visit the GP  17374 19357 
f_GPvisit_if_sympt_reduced  Freq of GP visits when sympt are reduced  18740 18388 
f_spec_consult_if_sympt_reduced  Freq of specialist consult when sympt reduced  18740 18388 
nr_of_days_on_afipram drug used by patients who have AE (nausea)  18568 18554 
pgoodresponse_cital probability of good response for citalopram 13672 173302 
pgoodresponse_escit prob of the good response for escitalopram DOMINATED 14127  
p_AEstrong_cital very strong adverse effects, poor tolerability 17254 24530  
p_AEstrong_escit prob that escit will have very strong adv. effects 23805 17335  
p_noresponse_cit at week 8 no response to drug  15340 249234  
p_noresponse_escit at week 8 no response to drug  179690 15517  
p_outpatient_second_care_cit Pat will be treated as outpat in citalopram group  14509 22596  
p_outpatient_second_care_escit patient will be tr. as outpatient in escit group  21973 15137  
p_switch_after_strong_AE_cit prob of switching due to adverse events on cit  17841 19324  
p_switch_after_strong_AE_escit prob of switch due to adverse events on escit  19268 17892  
p_sympt_pers_after_goodresp_cit symp are still persist after pat resp well on cit  24859 13060  
p_sympt_pers_after_goodresp_escit symp persist after pat resp well on escit  11164 27519  
p_sympt_pers_after_increase_cit symp will still pers after cital dose is increased  27982 10832  
p_sympt_pers_after_increase_escit symp will still pers after escit dose is increased  27982 10832  
p_sympt_pers_after_switch_cit symp will persist after cit will be switched  20408 16798  
p_sympt_pers_after_switch_escit sympt will persist after escit will be switched  16921 20273  
p_sympt_red_after_discont_cit sympt will be red after pat has discont cit  17910 19270  
p_sympt_red_after_discont_escit sympt will be red after pat disc treat with escit  19217 17955  
p_sympt_red_after_inpat_cit sympt will be red after pat in cital to sec care   5952 18744  
p_sympt_red_after_inpat_escit symp will be red after pat escit  go to sec care  5037 6069  
p_sympt_red_after_outpat_cit after outp care,prob that pat will have sympt red  5035 26849  
p_sympt_red_after_outpat_escit after outpat care pat will have symptom red  6597 5062  
qdays_cital_before_discontinuat  Nr of days on citalo before discontinuation  18624 18504  
qdays_escit_before_discontinuat  Nr of days on escit before discontinuation  18405 18721  
qdays_on_cital_before_dropout drop out, measured at week 4  18674 18420  
qdays_on_escit_before_dropout  Number of days on escit before drop out  18377 18807  
q_days_good_resp_cital nr days when good response to citalopram  20336 15906  
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q_days_good_resp_escit nr of days when  resp good to escitalopram  11433 29260  
q_days_on_cital_before_increase  Nr of days on citalopr before increased dose  19207 17921  
q_days_on_escit_before_increase  Nr of days on escitalopr before increased dose 17065  20063  
q_days_on_switched_SNRI nr of days on venlafaxine  18650 18507  
q_of_days_in_hospital average nr of days spent inpatient  19335 14708  
q_of_days_on_cital_before_switch  Nr of days on citalopram before switch  18704 18470  
q_of_days_on_escit_before_switch  Nr of days on escitalopram before switch  18195 18810  
q_of_days_on_increased_cital  Nr of days on increased citalopram  21006 16732  
q_of_days_on_increased_escit  Nr of days on increased escitalopram  12968 22761  
q_workdays_lost_primarycare nr of days pat have lost from work primary c.  13324 21708  
q_workdays_lost_secondarycare nr of days patient has lost, by using sec. Care  31096 12276  
 
 
 
 
 
 
 
 
 
 
 
 
 
 60
Appendix IV MADRS questionnaire 
MADRS  
(MONTGOMERY AND ASBERG DEPRESSION RATING SCALE) 
Br. J. Psychiat. (1979), 134, 382-389 
 
The rating should be based on a clinical interview moving from broadly phrased questions about symptoms to 
more detailed ones which allow a precise rating of severity. The rater must decide whether the rating lies on the 
defined scale steps (0, 2, 4, 6) or between them (1, 3, 5) and then report the appropriate number. The items should 
be rated with regards to how the patient has done over the past week.   
1 - APPARENT SADNESS - Representing despondency, gloom and despair, (more than just ordinary transient 
low spirits) reflected in speech, facial expression, and posture. Rate by depth and inability to brighten up. 
  0 No sadness 
  1   
  2 Looks dispirited but does brighten up without difficulty 
  3   
  4 Appears sad and unhappy most of the time 
  5   
  6 Looks miserable all the time. Extremely despondent. 
 
2 - REPORTED SADNESS - Representing reports of depressed mood, regardless of whether it is reflected in 
appearance or not. Includes low spirits, despondency or the feeling of being beyond help and without hope. Rate 
according to intensity, duration and the extent to which the mood is reported to be influenced by events. 
  0 Occasional sadness in keeping with the circumstances. 
  1   
  2 Sad or low but brightens up without difficulty. 
  3   
  4 Pervasive feelings of sadness or gloominess. The mood is still influenced by external circumstances.  
  5   
  6 Continuous or unvarying sadness, misery or despondency.  
 
3 - INNER TENSION - Representing feelings of ill-defined discomfort, edginess, inner turmoil, mental tension 
mounting to either panic, dread or anguish. Rate according to intensity, frequency, duration and the extent of 
reassurance called for. 
  0 Placid. Only fleeting inner tension.  
  1   
  2 Occasional feelings of edginess and ill-defined discomfort 
  3   
  4 Continuous feelings of inner tension or intermittent panic which the patient can only master with some difficulty. 
  5   
  6 Unrelenting dread or anguish. Overwhelming panic.  
 
4 - REDUCED SLEEP - Representing the experience of reduced duration or depth of sleep compared to the 
subject's own normal pattern when well. 
  0 Sleeps as usual. 
  1   
  2 Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep 
  3   
  4 Sleep reduced or broken by at least two hours. 
  5   
  Less than two or three hours sleep. 
 
6 
5 - REDUCED APPETITE - Representing the feeling of a loss of appetite compared with when well. Rate by loss 
of desire for food or the need to force oneself to eat. 
  0 Normal or increased appetite. 
  1   
  2 Slightly reduced appetite 
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  3   
  4 No appetite. Food is tasteless. 
  5   
6 Needs persuasion to eat at all.    
6 - CONCENTRATION DIFFICULTIES - Representing difficulties in collecting one's thoughts mounting to 
incapacitating lack of concentration. Rate according to intensity, frequency, and degree of incapacity produced. 
  0 No difficulties in concentrating. 
  1   
  2 Occasional difficulties in collecting one's thoughts. 
  3   
  4 Difficulties in concentrating and sustaining thought which reduces ability to read or hold a conversation. 
  5   
6 Unable to read or converse without great difficulty.   
7 - LASSITUDE - Representing a difficulty getting started or slowness initiating and performing everyday 
activities. 
  0 Hardly any difficulties in getting started. No sluggishness.  
  1   
  2 Difficulties in starting activities. 
  3   
  4 Difficulties in starting simple routine activities, which are carried out with effort.  
  5   
6 Complete lassitude. Unable to do anything without help.    
8 - INABILITY TO FEEL - Representing the subjective experience of reduced interest in the surroundings, or 
activities that normally give pleasure.The ability to react with adequate emotion to circumstances or people is 
reduced. 
  0 Normal interest in the surroundings and in other people. 
  1   
  2 Reduced ability to enjoy usual interests. 
  3   
  4 Loss of interest in the surroundings. Loss of feelings for friends and acquaintances. 
  5   
6 The experience of being emotionally paralyzed, inability to feel anger, grief or pleasure and a 
complete or even painful failure to feel for close relatives and friends.   
9 - PESSIMISTIC THOUGHTS - Representing thoughts of guilt, inferiority, self-reproach, sinfulness, remorse 
and ruin. 
  0 No pessimistic thoughts. 
  1   
  2 Fluctuating ideas of failure, self-reproach or self-depreciation. 
  3   
  4 Persistent self-accusations, or definite but still rational ideas of guilt or sin. Increasingly pessimistic about the future. 
  5   
6 Delusions of ruin, remorse and unredeemable sin. Self-accusations which are absurd and 
unshakable.   
10 - SUICIDAL THOUGHTS - Representing the feeling that life is not worth living, that a natural death would 
be welcome, suicidal thoughts, and preparations for suicide. Suicidal attempts should not in themselves influence 
the rating. 
  0 Enjoys life or takes it as it comes.  
  1   
  2 Weary of life. Only fleeting suicidal thoughts. 
  4 Probably better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without specific plans or intention. 
6 Explicit plans for suicide when there is an opportunity. Active preparations for suicide.   
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